# Intravenous Ribavirin Protocol to Treat Individuals With Viral Hemorrhagic Fever

> **NCT02483260** · NA · ENROLLING_BY_INVITATION · sponsor: **U.S. Army Medical Research and Development Command** · enrollment: 30 (estimated)

## Conditions studied

- Viral Hemorrhagic Fever

## Interventions

- **DRUG:** Ribavirin

## Key facts

- **NCT ID:** NCT02483260
- **Lead sponsor:** U.S. Army Medical Research and Development Command
- **Sponsor class:** FED
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** ENROLLING_BY_INVITATION
- **Start date:** 2016-06-16
- **Primary completion:** 2027-10
- **Final completion:** 2028-12
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2025-06-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02483260

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02483260, "Intravenous Ribavirin Protocol to Treat Individuals With Viral Hemorrhagic Fever". Retrieved via AI Analytics 2026-07-18 from https://api.ai-analytics.org/clinical/NCT02483260. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*